Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

INTRODUCTION: The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with wa...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lupus
Päätekijät: Cohen, H, Doré, C J, Clawson, S, Hunt, B J, Isenberg, D, Khamashta, M, Muirhead, N
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2015
Aiheet:
Special Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4527976/
https://ncbi.nlm.nih.gov/pubmed/25940537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203315581207
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia